EMA — authorised 20 September 2018
- Marketing authorisation holder: TETRAPHASE PHARMS
- Status: approved
🇪🇺 Xerava in European Union
EMA authorised Xerava on 20 September 2018
Marketing authorisations
EMA — authorised 20 September 2018
- Application: EMEA/H/C/004237
- Marketing authorisation holder: PAION Pharma GmbH
- Local brand name: Xerava
- Indication: Xerava is indicated in adolescents from the age of 12 years weighing at least 50 kg, and in adults, for the treatment of complicated intra-abdominal infections (cIAI). Consideration should be given to official guidance on the appropriate use of antibacterial agents.
- Status: approved
Xerava in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Infectious Disease approved in European Union
Frequently asked questions
Is Xerava approved in European Union?
Yes. EMA authorised it on 20 September 2018; EMA authorised it on 20 September 2018.
Who is the marketing authorisation holder for Xerava in European Union?
TETRAPHASE PHARMS holds the EU marketing authorisation.